title: Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma.
abstract: OBJECTIVE
  To evaluate quality of life (QOL) and tumor response after administration of an oral chemotherapy regimen in patients with previously untreated metastatic colorectal cancer.
  
  
  METHODS
  Seventy-eight patients received a mean number of 5.8 cycles of therapy. QOL data were analyzed at baseline, after every two cycles of therapy, and at the time of treatment discontinuation. The Uniscale and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 were both utilized.
  
  
  RESULTS
  The confirmed response rate was 26% (95% confidence interval [CI], 17% to 37%). Median survival was 11.3 months (95% CI, 9.6 to 15.1 months). Global QOL scores were unchanged over the course of therapy by either tool. Only the physical function subscale score had worsened at the end of therapy. In an analysis of responding patients, significant and durable improvements in both global QOL measures as well as select subscale scores were observed. Diarrhea and physical function QOL scores had declined at the time of treatment discontinuation. Patients who did not respond to therapy had preserved QOL scores when they were evaluated after two cycles of therapy.
  
  
  CONCLUSIONS
  This oral treatment strategy preserved QOL in treated patients. Global QOL measures as well as several QOL subscale scores significantly improved in patients with a documented response to therapy. The profile of improved QOL components indicated that patient well-being was related to tumor response in specific and perceivable ways. Nonresponding patients reported preserved QOL during the first two cycles of therapy. QOL analysis was feasible and informative in this moderately sized multicenter phase II trial.
authors.affiliation: Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. hobday.timothy@mayo.edu
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Hobday
authors.forename: John W
authors.initials: JW
authors.lastname: Kugler
authors.forename: Michelle R
authors.initials: MR
authors.lastname: Mahoney
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Sargent
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Sloan
authors.forename: Tom R
authors.initials: TR
authors.lastname: Fitch
authors.forename: James E
authors.initials: JE
authors.lastname: Krook
authors.forename: Michael J
authors.initials: MJ
authors.lastname: O'Connell
authors.forename: James A
authors.initials: JA
authors.lastname: Mailliard
authors.forename: Maria Tria
authors.initials: MT
authors.lastname: Tirona
authors.forename: Loren K
authors.initials: LK
authors.lastname: Tschetter
authors.forename: Charles D
authors.initials: CD
authors.lastname: Cobau
authors.forename: Richard M
authors.initials: RM
authors.lastname: Goldberg
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome